Cabaletta Bio, Inc. (CABA)
Market Cap | 236.00M |
Revenue (ttm) | n/a |
Net Income (ttm) | -52.98M |
Shares Out | 31.34M |
EPS (ttm) | -1.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 210,292 |
Open | 7.31 |
Previous Close | 7.47 |
Day's Range | 7.20 - 7.58 |
52-Week Range | 0.59 - 12.88 |
Beta | 2.57 |
Analysts | Buy |
Price Target | 13.77 (+82.87%) |
Earnings Date | May 11, 2023 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune b... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $13.77, which is an increase of 82.87% from the latest price.
News

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical...

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy
Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cabaletta Bio, Inc. (CABA) Is a Great Choice for 'Trend' Investors, Here's Why
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th...

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

4 Drug Stocks That More Than Doubled This Year
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Can Cabaletta Bio, Inc. (CABA) Climb 60% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

5 Stocks Insiders Are Buying in October
According to the Insider Cluster Buys screen, a Premium feature of GuruFocus, five stocks that had a high number of company insiders buying shares over the past month were CNB Financial Corp. ( CCNE ,...

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy
PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patie...

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for pati...

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial
PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patie...

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patie...

What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock
Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cabaletta Bio's Updated Interim DSG3-CAART Data Fails To Cheer Investors
Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV), a blistering skin disease that affect...

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting
PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patien...

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update
– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 –

Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patien...

CABA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cabaletta Bio, Inc
New York, New York--(Newsfile Corp. - April 29, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cabaletta Bio, In...

CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - April 29, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) allegi...

Bronstein, Gewirtz & Grossman, LLC Reminds Cabaletta Bio, Inc. (CABA) Investors of Class Action Deadline and Last Few Hours to Actively Participate
New York, New York--(Newsfile Corp. - April 29, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "th...

CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
New York, New York--(Newsfile Corp. - April 29, 2022) - Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsu...

Deadline Today Alert: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - April 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cabaletta Bio, I...